Lung Cancer Advisory Board

Hatim Husain, M.D.

Dr. Husain is a lung cancer medical oncologist pursuing a translational career in cancer therapeutic strategies in solid tumor malignancies. His passion is to be involved in early drug development, and his goal is to develop a translational laboratory for biomarker validation and drug testing in in vitro and in vivo models that can form the basis for early phase clinical trials. He works very closely to characterize technology development in the circulating tumor DNA space and applications about its utility. He has also recently been involved in understanding mechanisms of resistance to anti-EGFR directed therapies and further understanding the mechanisms of immunogenic cell death in cancer cells.

Gregory Otterson, M.D.

Dr. Otterson is Professor in the College of Medicine at Ohio State University (OSU) Comprehensive Cancer Center James Cancer Hospital. Dr. Otterson is broadly interested in improving the care and understanding of thoracic malignancies (adenocarcinoma, squamous carcinoma, large cell carcinoma, never-smoking adenocarcinoma, small cell lung cancer, mesothelioma, and thymic cancers). His research centers around the genetic and epigenetic changes in lung cancers, particularly microRNAs. Therapeutically, he is interested in understanding how better to target specific therapies to specific patients, that is, understanding which patients will respond to which therapeutic maneuvers. Dr. Otterson has active collaborations within OSU, including in the Division of Cancer Genetics (Carlo Croce), the School of Public Health (Mary Ellen Wewers and Amy Ferketich), and the Division of Pulmonary and Critical Care Medicine (Patrick Nana-Sinkam). Outside of OSU, he works with investigators at the University of Minnesota and also actively works with the Cancer and Leukemia Group B, having been National Principal Investigator on three studies through the Respiratory Committee.


David Spigel, M.D.

Dr. Spigel serves as Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. He joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon’s clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.

Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.

Emeritus Lung Cancer Advisory Board

Phillip Dennis, M.D., Ph.D.
Nicholas Campbell, M.D.
Raphael Bueno, M.D.
Ravi Salgia, M.D., Ph.D.
George Simon, M.D.